Company intelligence / Profile preview

Peak Bio, Inc.

Pleasanton, California, United Statespeak-bio.com ↗

Ownership: Private
Employees: ~6
Development stage: Other

Overview

Lead program PHP‑303 reached Phase II readiness for AATD. The company also developed a proprietary ADC platform targeting oncology indications. After merging with Akari Therapeutics in late 2024, the combined entity continues development of these assets alongside new autoimmune/inflammatory disease programs.

Therapeutic areas: OncologyPulmonologyRare DiseasesImmunology
Modalities: Small moleculesMonoclonal antibodies (mAbs)Antibody-drug conjugates (ADCs)
Industry: Biotech

Beyond the preview

Go deeper on Peak Bio, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peak Bio, Inc..